LectureRechercheRadarCadre d'investissement
Connexion / Inscription
← Retour à la lecture
ActualitésSujet · 金迪克疫苗退市风险Matériel1 min de lectureRédaction DisconfirmAI

Jindike Shares Plunge as Approved Flu Vaccine Faces Sales Delay and Delisting Risk

Approval does not equal availability; batch release delays cause Jindike to miss the flu season sales window, triggering revenue collapse and delisting warnings.

2026-10-12 17:53 GMT+8

Jindike (688670.SH) shares fell 19.98% to close at 15.34 yuan on October 12, despite the recent approval of its trivalent influenza vaccine.

The decline stems from a regulatory bottleneck: while the product is approved, it requires up to 45 days for batch release before it can be sold. Influenza vaccines have a strict seasonal sales window from September to December, meaning any delay results in a complete loss of annual revenue potential.

Financial data highlights the severity: Jindike's revenue for the first half of 2026 was only 910,000 yuan, compared to 113 million yuan for all of 2025. The company warned that full-year revenue may fall below 100 million yuan with no profit turnaround, potentially triggering financial delisting risk warnings.

This case illustrates a specific investment risk in biopharma: for small-cap companies dependent on single seasonal products, the time lag between approval and market availability can threaten survival rather than just impact quarterly earnings.

Sources

  • eeo.com.cn↗
Sujet

金迪克疫苗退市风险

金迪克(688670.SH)因三价流感疫苗获批时间过晚,错过2026-2027流感季销售窗口,面临营收断档及退市风险警示。

Connexion / Inscription
LectureRechercheRadarCadre d'investissement

4 étapes1 piècesMis à jour 2026-10-12 21:30

Comment on en est arrivé là

  1. 2026-02-27世卫组织发布2026-2027北半球流感疫苗推荐组分,剔除B/Yamagata系,三价疫苗成为主流。finance.biggo.com ↗
  2. 2026-08-20金迪克发布半年报,上半年营收仅91.09万元,净亏损5107万元,同比大幅下滑。finance.biggo.com ↗
  3. 2026-10-09金迪克公告三价流感疫苗获国家药监局注册证书,但同时预警全年营收或低于1亿元,触及退市风险。sohu.com ↗

Ce qui reste non résolu

  • 11月底完成批签发后,金迪克能否在剩余的流感季窗口期获得足够的地方疾控采购订单?
  • 面对国内已获批的20余款三价流感疫苗,金迪克是否有明确的定价或推广策略以应对价格战?
  • 若2026年触发退市风险警示,2027年的业绩表现是否足以避免终止上市?
Lire le sujet complet →
Continuer la recherche →